COMPOSITIONS FOR THE TREATMENT OF JOINTS
A composition for treating a joint condition, the composition comprising: hyaluronic acid; and taurolidine.
1 . A composition for treating a joint condition, the composition comprising:
hyaluronic acid; and
taurolidine.
2 . A composition according to claim 1 wherein the hyaluronic acid has a concentration of at least approximately 5 mg/ml.
3 . A composition according to claim 1 wherein the hyaluronic acid has a concentration of at least approximately 7 mg/ml.
4 . A composition according to claim 1 wherein the hyaluronic acid has a concentration of at least approximately 10 mg/ml.
5 . A composition according to claim 1 wherein the hyaluronic acid has a concentration of at least approximately 15 mg/ml.
6 . A composition according to claim 1 wherein the hyaluronic acid has a concentration of at least approximately 20 mg/ml.
7 . A composition according to claim 1 wherein the hyaluronic acid has a concentration of at least approximately 60 mg/ml.
8 . A composition according to claim 1 wherein the hyaluronic acid has a molecular weight of at least about 500 kDa.
9 . A composition according to claim 1 wherein the hyaluronic acid has a molecular weight of at least about 1 MDa.
10 . A composition according to claim 1 wherein the hyaluronic acid has a molecular weight of about 1-4 MDa.
11 . A composition according to claim 1 wherein the taurolidine comprises approximately 6% or less of the composition by weight.
12 . A composition according to claim 11 wherein the taurolidine comprises approximately 2% or less of the composition by weight.
13 . A composition according to claim 1 further comprising at least one bone morphogenetic protein (BMP).
14 . A composition according to claim 13 wherein the at least one BMP comprises one from the group consisting of BMP2, BMP7, GDF-5, GDF-6, and GDF-7.
15 . A composition according to claim 13 wherein the BMP is at a concentration of at least approximately 0.1 μg/ml.
16 . A composition according to claim 13 wherein the BMP is at a concentration of at least approximately 5 μg/ml.
17 . A composition according to claim 13 wherein the BMP is at a concentration of at least approximately 50 μg/ml.
18 . A composition according to claim 13 wherein the BMP is at a concentration of at least approximately 200 μg/ml.
19 . A composition according to claim 13 wherein the BMP is at a concentration of at least approximately 500 μg/ml.
20 . A composition according to claim 13 wherein the BMP is at a concentration of at least approximately 2000 μg/ml.
21 . A kit comprising:
a first component comprising hyaluronic acid and an taurolidine; and
a second component comprising a bone morphogenetic protein (BMP).
22 . A kit according to claim 21 wherein the BMP is in solid form.
23 . A kit according to claim 22 further comprising a syringe for injecting a mixture of the first component and the second component.
24 . A kit according to claim 23 wherein the syringe has a first chamber containing the first component, and a second chamber containing the second component, and further wherein the syringe is configured to mix the first component and second component together at the time of use.
25 . A method for treating a patient, the method comprising:
providing a composition comprising:
hyaluronic acid; and
taurolidine; and
introducing the composition into a joint of the patient.
26 . A method according to claim 25 wherein the composition further comprises at least one bone morphogenetic protein (BMP).
27 . A composition for treating a joint condition, the composition comprising:
hyaluronic acid; and
nanoparticles comprising a taurolidine core surrounded by a lipophilic coating.
28 . A composition according to claim 27 wherein the hyaluronic acid comprises a hydrogel.
29 . A composition according to claim 28 wherein the hydrogel metabolizes to provide a tissue scaffold and expose the nanoparticles to bodily fluids.
30 . A composition according to claim 29 wherein the tissue scaffold provided by the metabolized hydrogel helps maintain the taurolidine core at the appropriate anatomical location as bone tissue grows into the tissue scaffold.
31 . A composition according to claim 27 wherein the taurolidine core comprises a saturated solution of taurolidine.
32 . A composition according to claim 27 wherein the lipophilic coating comprises lipophilic peptides.
33 . A composition according to claim 32 wherein the lipophilic coating comprises mixtures of mono-, di-, and tri-glycerides.
34 . A composition according to claim 32 wherein the lipophilic coating comprises at least one from the group consisting of valine, leucine, proline, phenylalanine and tryptophan, or combinations of the peptides.
35 . A composition according to claim 27 wherein, when the nanoparticles are exposed to bodily fluids, the lipophilic coating is metabolized to release the taurolidine core.
36 . A composition according to claim 35 wherein the taurolidine core spontaneously hydrolyzes to active methylol moieties when the lipophilic coating is metabolized.